1.Cicero, T. Effects of exogenous and endogenous opiates on the hypothalamicpituitary-gonadal axis in the male. Fed Proc 1980; 39(8): 2551–2554.
2.Drolet, G, Dumont, EC, Gosselin, I, Kinkead, R, Laforest, S, Trottier, JF. Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psy 2001; 25(4): 729–741.
3.Genazzani, AR, Genazzani, AD, Volpogni, Cet al.Opioid control of gonadotrophin secretion in humans. Hum Reprod 1993; 8(2): 151–153.
4.Grossman, A, Moult, PJ, Gaillard, RCet al.The opioid control of LH and FSH release: effects of a met-enkephalin analogue and naloxone. Clin Endocr (Oxf) 1981; 14(1): 41–47.
5.Jordan, D, Tafani, JAM, Ries, Cet al.Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocr 1996; 8: 883–887.
6.Veldhuis, JD, Rogol, AD, Samojlik, E, Ertel, N. Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man. J Clin Invest 1984; 74:47–55.
7.Ceccarelli, I, De Padova, AM, Fiorenzani, P, Massafra, C, Aloisi, AM. Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats. Neurosc 2006; 140: 929–937.
8.De la rossa, RE, Hennessey, JV. Hypogonadism and methadone: Hypothalamic hypogonadism after long-term use of high dose methadone. Endocr Pract 1996; 2: 4–7.
9.Bliesener, N, Albrecht, S, Schwager, A, Weckbecker, K, Lichtermann, D, Klingmuller, D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endoc Metab 2005; 90: 203–206.
10.Yen, SSC, Quigley, ME, Reid, RLet alNeuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obst Gyn 1985; 152: 485–493.
11.Daniel, HW. Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis 2002; 21(4): 47–53.
12.Mendelson, JH, Mello, NK. Plasma testosterone levels during chronic heroin use and protracted abstinence. A study of Hong Kong addicts. Clin Pharmacol Ther 1975; 17(5): 529–533.
13.Dorlands pocket medical dictionary, 26th ed. 2001: 417.
14.Stanworth, RD, Jones, TH. Testosterone for the ageing male; current evidence and recommended practice. Clin Interv Aging 2008; 3: 25–44.
15.Daniel, HW. Opioid-induced androgen defiency. Current Opinion in Endocr Diab 2006; 13(3): 262–266.
16.Daniel, HW. Opioid Endocrinopathy in Women Consuming Prescribed Sustained-Action Opioids for Control of Non-malignant Pain. J Pain 2008; 9(1): 28–36.
17.Zylicz, Z. Opioid-induced hypognadism: the role of androgens in the well-being and pain thresholds in men and women with advanced disease. Adv Pall Med 2009; 8(2): 57–62.
19.Molly, MS, Alvin, MM, Kevin, LS, Daniel, RK. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660–1665.
20.Rhoden, EL, Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.